gabapentin has been researched along with Parkinson Disease in 15 studies
Gabapentin: A cyclohexane-gamma-aminobutyric acid derivative that is used for the treatment of PARTIAL SEIZURES; NEURALGIA; and RESTLESS LEGS SYNDROME.
gabapentin : A gamma-amino acid that is cyclohexane substituted at position 1 by aminomethyl and carboxymethyl groups. Used for treatment of neuropathic pain and restless legs syndrome.
Parkinson Disease: A progressive, degenerative neurologic disease characterized by a TREMOR that is maximal at rest, retropulsion (i.e. a tendency to fall backwards), rigidity, stooped posture, slowness of voluntary movements, and a masklike facial expression. Pathologic features include loss of melanin containing neurons in the substantia nigra and other pigmented nuclei of the brainstem. LEWY BODIES are present in the substantia nigra and locus coeruleus but may also be found in a related condition (LEWY BODY DISEASE, DIFFUSE) characterized by dementia in combination with varying degrees of parkinsonism. (Adams et al., Principles of Neurology, 6th ed, p1059, pp1067-75)
| Excerpt | Relevance | Reference |
|---|---|---|
| "To review the use of the antiepileptic drug gabapentin for the treatment of various types of tremor." | 8.82 | Gabapentin for the treatment of tremor. ( Bertoni, JM; Faulkner, MA; Lenz, TL, 2003) |
| "To review the use of the antiepileptic drug gabapentin for the treatment of various types of tremor." | 4.82 | Gabapentin for the treatment of tremor. ( Bertoni, JM; Faulkner, MA; Lenz, TL, 2003) |
| " We compared new users of recently approved versus established medications for management of diabetic peripheral neuropathy (pregabalin versus gabapentin), Parkinson disease psychosis (pimavanserin versus quetiapine), and epilepsy (brivaracetam versus levetiracetam)." | 4.31 | Channeling of New Neuropsychiatric Drugs-Impact on Safety and Effectiveness Studies. ( Abraham, DS; Blank, LJ; Gray, SL; Hennessy, S; Leonard, CE; Nguyen, TPP; Thibault, D; Weintraub, D; Willis, AW, 2023) |
| "We identified 52,249 patients with neuropathy on gabapentinoids, 5,246 patients with neuropathy on SNRIs, 19,820 patients with dementia on cholinesterase inhibitors, and 3,130 patients with PD on dopamine agonists." | 3.96 | Association of out-of-pocket costs on adherence to common neurologic medications. ( Banerjee, M; Burke, JF; Callaghan, BC; Esper, GJ; Kerber, KA; Magliocco, B; Reynolds, EL; Skolarus, LE, 2020) |
| "The phenytoin treatment causes cerebellar defect and anemia." | 2.82 | The interplay of epilepsy with impaired mitophagy and autophagy linked dementia (MAD): A review of therapeutic approaches. ( Agrawal, M; Dhurandhar, Y; Panda, SP, 2022) |
| "Monosymptomatic rest tremor has recently been shown to be associated with decreased fluorodopa uptake on the positron emission tomography scan suggesting its relationship to Parkinson disease." | 2.42 | Tremor. ( Sethi, KD, 2003) |
| "Essential tremor is a common movement disorder in adults that interferes with the performance of functional and social activities." | 2.42 | Essential tremor: diagnosis and treatment. ( Chen, JJ; Swope, DM, 2003) |
| "Tremor-predominant Parkinson's disease is characterised by prominent tremor of one or more limbs with a relative lack of significant rigidity and bradykinesia." | 2.41 | Tremor-predominant Parkinson's disease. Approaches to treatment. ( Koller, W; Marjama-Lyons, J, 2000) |
| "Chronic pain is the most common non-motor symptom among Parkinson's disease (PD) patients, with 1." | 1.51 | Effects of subthalamic deep brain stimulation with gabapentin and morphine on mechanical and thermal thresholds in 6-hydroxydopamine lesioned rats. ( Feustel, P; Kaszuba, BC; Maietta, T; Pilitsis, JG; Shin, DS; Slyer, J; Stapleton, A; Walling, I, 2019) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 1 (6.67) | 18.2507 |
| 2000's | 8 (53.33) | 29.6817 |
| 2010's | 3 (20.00) | 24.3611 |
| 2020's | 3 (20.00) | 2.80 |
| Authors | Studies |
|---|---|
| Panda, SP | 1 |
| Dhurandhar, Y | 1 |
| Agrawal, M | 1 |
| Abraham, DS | 1 |
| Nguyen, TPP | 1 |
| Blank, LJ | 1 |
| Thibault, D | 1 |
| Gray, SL | 1 |
| Hennessy, S | 1 |
| Leonard, CE | 1 |
| Weintraub, D | 1 |
| Willis, AW | 1 |
| Reynolds, EL | 1 |
| Burke, JF | 1 |
| Banerjee, M | 1 |
| Kerber, KA | 1 |
| Skolarus, LE | 1 |
| Magliocco, B | 1 |
| Esper, GJ | 1 |
| Callaghan, BC | 1 |
| Hsu, CH | 1 |
| Yu, SM | 1 |
| Lau, SC | 1 |
| Chen, YL | 1 |
| Pei, D | 1 |
| Liu, IC | 1 |
| Kaszuba, BC | 1 |
| Maietta, T | 1 |
| Walling, I | 1 |
| Feustel, P | 1 |
| Stapleton, A | 1 |
| Shin, DS | 1 |
| Slyer, J | 1 |
| Pilitsis, JG | 1 |
| Ege, F | 1 |
| Koçak, Y | 1 |
| Titiz, AP | 1 |
| Oztürk, SM | 1 |
| Oztürk, S | 1 |
| Ozbakir, S | 1 |
| Erol, C | 1 |
| Ozben, S | 1 |
| Ozer, F | 1 |
| Cetin, S | 1 |
| Tiras, R | 1 |
| Sarbaz, Y | 1 |
| Gharibzadeh, S | 1 |
| Towhidkhah, F | 1 |
| Faulkner, MA | 1 |
| Bertoni, JM | 1 |
| Lenz, TL | 1 |
| Sethi, KD | 1 |
| Chen, JJ | 1 |
| Swope, DM | 1 |
| Raju, PM | 1 |
| Walker, RW | 1 |
| Lee, MA | 1 |
| Poujois, A | 1 |
| Vidailhet, M | 1 |
| Trocello, JM | 1 |
| Bourdain, F | 1 |
| Gaymard, B | 1 |
| Rivaud-Péchoux, S | 1 |
| Chaná, P | 1 |
| de Marinis, A | 1 |
| Barrientos, N | 1 |
| Marjama-Lyons, J | 1 |
| Koller, W | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Comparison of Oral Gabapentin and Pregabalin in Postoperative Pain Control After Photorefractive Keratectomy: a Prospective, Randomized Study.[NCT00954187] | 8 participants (Actual) | Interventional | 2009-11-30 | Terminated (stopped due to PI left institution) | |||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
5 reviews available for gabapentin and Parkinson Disease
| Article | Year |
|---|---|
The interplay of epilepsy with impaired mitophagy and autophagy linked dementia (MAD): A review of therapeutic approaches.
Topics: Anticonvulsants; Carbamazepine; Dementia; Epilepsy; Felbamate; Gabapentin; Humans; Inflammasomes; La | 2022 |
Gabapentin for the treatment of tremor.
Topics: Acetates; Adult; Aged; Amines; Clinical Trials as Topic; Cyclohexanecarboxylic Acids; Gabapentin; ga | 2003 |
Tremor.
Topics: Acetates; Amines; Anticonvulsants; Antiparkinson Agents; Cyclohexanecarboxylic Acids; Diagnosis, Dif | 2003 |
Essential tremor: diagnosis and treatment.
Topics: Acetates; Amines; Cyclohexanecarboxylic Acids; Diagnosis, Differential; Essential Tremor; Gabapentin | 2003 |
Tremor-predominant Parkinson's disease. Approaches to treatment.
Topics: Acetates; Amantadine; Amines; Antiparkinson Agents; Botulinum Toxins; Cholinergic Antagonists; Clona | 2000 |
2 trials available for gabapentin and Parkinson Disease
| Article | Year |
|---|---|
Effect of gabapentin on oculomotor control and parkinsonism in patients with progressive supranuclear palsy.
Topics: Aged; Amines; Antiparkinson Agents; Cyclohexanecarboxylic Acids; Eye Movements; Female; Gabapentin; | 2007 |
Gabapentin and motor fluctuations in Parkinson's disease.
Topics: Acetates; Aged; Amines; Antiparkinson Agents; Cyclohexanecarboxylic Acids; Drug Therapy, Combination | 1997 |
8 other studies available for gabapentin and Parkinson Disease
| Article | Year |
|---|---|
Channeling of New Neuropsychiatric Drugs-Impact on Safety and Effectiveness Studies.
Topics: Adult; Cross-Sectional Studies; Diabetic Neuropathies; Epilepsy; Gabapentin; Humans; Levetiracetam; | 2023 |
Association of out-of-pocket costs on adherence to common neurologic medications.
Topics: Adult; Aged; Antiparkinson Agents; Cholinesterase Inhibitors; Dementia; Excitatory Amino Acid Antago | 2020 |
Restless legs syndrome/Willis-Ekbom disease in type 2 diabetes as the initial manifestation of Parkinson's disease and major cardiovascular disease.
Topics: Aged; Amines; Analgesics; Anticonvulsants; Antihypertensive Agents; Antiparkinson Agents; Aspirin; B | 2017 |
Effects of subthalamic deep brain stimulation with gabapentin and morphine on mechanical and thermal thresholds in 6-hydroxydopamine lesioned rats.
Topics: Animals; Chronic Pain; Deep Brain Stimulation; Disease Models, Animal; Gabapentin; Male; Morphine; O | 2019 |
Gabapentin-Induced myoclonus: case report.
Topics: Aged, 80 and over; Amines; Antiparkinson Agents; Cyclohexanecarboxylic Acids; Gabapentin; gamma-Amin | 2008 |
Bilateral ballism induced by gabapentin in idiopatic Parkinson's disease.
Topics: Aged, 80 and over; Amines; Anticonvulsants; Back Pain; Comorbidity; Cyclohexanecarboxylic Acids; Dys | 2009 |
Pathophysiology of freezing of gait and some possible treatments for it.
Topics: Amines; Cyclohexanecarboxylic Acids; Dopamine; Excitatory Amino Acid Antagonists; Gabapentin; Gait; | 2012 |
Dyskinesia induced by gabapentin in idiopathic Parkinson's disease.
Topics: Aged; Amines; Antiparkinson Agents; Cyclohexanecarboxylic Acids; Dyskinesia, Drug-Induced; Gabapenti | 2007 |